Small molecule that inhibits androgen receptor could treat prostate cancer

Rosemary

Senior Member
Messages
193
Likes
1
Rosemary:
Maybe you should send this to WPI???? Or post it to their site? ~Fern
A good idea ! ... thanks Fern

Here is some further information

In vitro and mouse studies identified a small molecule from Geodia lindgreni that inhibits androgen receptor and could treat prostate cancer. Screening and in vitro testing of marine sponge extracts identified a compound that inhibited the N-terminal domain of androgen receptor. In three human prostate cancer cell lines, the compound reduced androgen receptor-dependent proliferation compared with no treatment. In mice with androgen-sensitive and castration-resistant prostate cancer (CRPC) xenografts, the compound reduced tumor growth compared with no treatment. Ongoing work includes optimization of the lead compound.
MDV3100, a triple-acting oral anti-androgen receptor from Medivation Inc. and Astellas Pharma Inc., is in Phase III testing to treat CRPC.
Tokai Pharmaceuticals Inc.'s TOK-001, a selective androgen receptor modulator (SARM) and inhibitor of cytochrome P450 17 a-hydroxylase/C17, 20 lyase (CYP17), is in Phase I/II testing to treat CRPC.
Aragon Pharmaceuticals Inc.'s ARN-509, a small molecule that binds androgen receptor, is in preclinical development to treat CRPC.

Patented by The University of British Columbia and the BC Cancer Agency; licensing status undisclosed

Andersen, R.J. et al. Cancer Cell; published online June 13, 2010;
doi:10.1016/j.ccr.2010.04.027
Contact: Marianne D. Sadar,
BC Cancer Agency, Vancouver,
British Columbia, Canada
e-mail:
msadar@bcgsc.ca